ReviewTrends in parasitology2020
The Journey to Discovering a Flatworm Target of Praziquantel: A Long TRP.
Review in Trends in parasitology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 84 citations in OpenAlex.
- Article
- Evaluation of the antiparasitic efficacy of praziquantel against Prohemistomum vivax (Cyathocotylidae) metacercariae in naturally infected African catfish (Clarias gariepinus).Scientific reports · 2026Article
- TRPtracker: a community database for monitoring praziquantel sensitivity at TRPMInternational journal for parasitology. Drugs and drug resistance · 2026Article
- Development of a Novel Compound Effective Against Juvenile, Adult, and Drug-ResistantPharmaceutics · 2025Review
- Target-Based Design of Praziquantel Analogs at Cestode TRPMACS infectious diseases · 2025Article
- Therapeutic challenges of schistosomiasis: mechanisms of action and current limitations.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025Review
- TRPtracker: a community database for monitoring praziquantel sensitivity at TRPMbioRxiv : the preprint server for biology · 2025Article
- Comment on: Target-based discovery of a broad-spectrum flukicide.PLoS neglected tropical diseases · 2024Article
- Target-based discovery of a broad-spectrum flukicide.Nature structural & molecular biology · 2024Article
- Progress interrogating TRPMPZQ as the target of praziquantel.PLoS neglected tropical diseases · 2024Review
- TRP drop, TRP drop: a steady patter of anti-schistosomal target illumination.Frontiers in parasitology · 2024Review
- Praziquantel resistance in schistosomes: a brief report.Frontiers in parasitology · 2024Review
- Praziquantel and factor H recruitment differentially affect the susceptibility ofFrontiers in immunology · 2024Article
- Schistosomiasis.Advances in experimental medicine and biology · 2024Review
- The Anthelmintic Activity of Praziquantel Analogs Correlates with Structure-Activity Relationships at TRPMACS medicinal chemistry letters · 2023Article
- In vitro evaluation of the effect of galectins on Schistosoma mansoni motility.BMC research notes · 2023Article
- Target-based discovery of a broad spectrum flukicide.bioRxiv : the preprint server for biology · 2023Article
- Advances in new target molecules against schistosomiasis: A comprehensive discussion of physiological structure and nutrient intake.PLoS pathogens · 2023Review
- Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis.PLoS pathogens · 2023Article
- Use the force, fluke: Ligand-independent gating of Schistosoma mansoni ion channel TRPMInternational journal for parasitology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Infections caused by parasitic flatworms impose a considerable worldwide health burden. One of the most impactful is schistosomiasis, a disease caused by parasitic blood flukes. Treatment of schistosomiasis has relied on a single drug - praziquantel (PZQ) - for decades. The utility of PZQ as an essential medication is, however, intertwined with a stark gap in our knowledge as to how this drug works. No flatworm target has been identified that readily explains how PZQ paralyzes and damages schistosomes. Recently, a schistosome ion channel was discovered that is activated by PZQ and displays characteristics which mirror key features of PZQ action on schistosomes. Here, the journey to discovery of this target, properties of this ion channel, and remaining questions are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.